Literature DB >> 29255172

Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.

Eleonora Ingallina1, Giovanni Sorrentino1,2, Rebecca Bertolio1,3, Kamil Lisek1,4, Alessandro Zannini1,3, Luca Azzolin5, Luisa Ulloa Severino3,6, Denis Scaini3,6, Miguel Mano7,8, Fiamma Mantovani1,3, Antonio Rosato9, Silvio Bicciato10, Stefano Piccolo5, Giannino Del Sal11,12.   

Abstract

Tumour-associated p53 missense mutants act as driver oncogenes affecting cancer progression, metastatic potential and drug resistance (gain-of-function) 1 . Mutant p53 protein stabilization is a prerequisite for gain-of-function manifestation; however, it does not represent an intrinsic property of p53 mutants, but rather requires secondary events 2 . Moreover, mutant p53 protein levels are often heterogeneous even within the same tumour, raising questions on the mechanisms that control local mutant p53 accumulation in some tumour cells but not in their neighbours 2,3 . By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment. Our results provide evidence for an unpredicted layer of mutant p53 regulation that relies on metabolic and mechanical cues.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29255172      PMCID: PMC6179142          DOI: 10.1038/s41556-017-0009-8

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  42 in total

1.  Mechanisms of mechanical signaling in development and disease.

Authors:  Paul A Janmey; R Tyler Miller
Journal:  J Cell Sci       Date:  2011-01-01       Impact factor: 5.285

2.  The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation.

Authors:  Claudia Esser; Martin Scheffner; Jörg Höhfeld
Journal:  J Biol Chem       Date:  2005-05-23       Impact factor: 5.157

3.  Ubiquitination and degradation of mutant p53.

Authors:  Natalia Lukashchuk; Karen H Vousden
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

4.  Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.

Authors:  T Koga; S Hashimoto; K Sugio; I Yoshino; K Nakagawa; Y Yonemitsu; K Sugimachi; K Sueishi
Journal:  Int J Cancer       Date:  2001-07-20       Impact factor: 7.396

5.  A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.

Authors:  Javier E Girardini; Marco Napoli; Silvano Piazza; Alessandra Rustighi; Carolina Marotta; Enrico Radaelli; Valeria Capaci; Lee Jordan; Phil Quinlan; Alastair Thompson; Miguel Mano; Antonio Rosato; Tim Crook; Eugenio Scanziani; Anthony R Means; Guillermina Lozano; Claudio Schneider; Giannino Del Sal
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

6.  A novel Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts.

Authors:  Olivier Destaing; Frédéric Saltel; Benoit Gilquin; Anne Chabadel; Saadi Khochbin; Stéphane Ory; Pierre Jurdic
Journal:  J Cell Sci       Date:  2005-07-01       Impact factor: 5.285

Review 7.  Protein prenylation: molecular mechanisms and functional consequences.

Authors:  F L Zhang; P J Casey
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

8.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

Authors:  Tamara Terzian; Young-Ah Suh; Tomoo Iwakuma; Sean M Post; Manja Neumann; Gene A Lang; Carolyn S Van Pelt; Guillermina Lozano
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

Review 9.  HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.

Authors:  C Boyault; K Sadoul; M Pabion; S Khochbin
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

10.  Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.

Authors:  Francesca Zanconato; Mattia Forcato; Giusy Battilana; Luca Azzolin; Erika Quaranta; Beatrice Bodega; Antonio Rosato; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Nat Cell Biol       Date:  2015-08-10       Impact factor: 28.824

View more
  46 in total

Review 1.  Context is everything: extrinsic signalling and gain-of-function p53 mutants.

Authors:  Ivano Amelio; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-03-23

2.  Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.

Authors:  Gu Xiao; George K Annor; Kimberly Fung; Outi Keinänen; Brian M Zeglis; Jill Bargonetti
Journal:  Mol Pharm       Date:  2020-12-08       Impact factor: 4.939

Review 3.  The stiff RhoAd from mevalonate to mutant p53.

Authors:  Giovanni Sorrentino; Fiamma Mantovani; Giannino Del Sal
Journal:  Cell Death Differ       Date:  2018-03-06       Impact factor: 15.828

4.  Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects.

Authors:  Zhihua Jiao; Huaqing Cai; Yu Long; Orit Katarina Sirka; Veena Padmanaban; Andrew J Ewald; Peter N Devreotes
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-12       Impact factor: 11.205

Review 5.  Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.

Authors:  Michele Carbone; Ivano Amelio; El Bachir Affar; James Brugarolas; Lisa A Cannon-Albright; Lewis C Cantley; Webster K Cavenee; Zhijian Chen; Carlo M Croce; Alan D' Andrea; David Gandara; Carlotta Giorgi; Wei Jia; Qing Lan; Tak Wah Mak; James L Manley; Katsuhiko Mikoshiba; Jose N Onuchic; Harvey I Pass; Paolo Pinton; Carol Prives; Nathaniel Rothman; Said M Sebti; James Turkson; Xifeng Wu; Haining Yang; Herbert Yu; Gerry Melino
Journal:  Cell Death Differ       Date:  2018-10-15       Impact factor: 15.828

6.  Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate.

Authors:  Mengjia Zhao; Pengbo Yao; Youxiang Mao; Jinjun Wu; Weihua Wang; Chenhui Geng; Jie Cheng; Wenjing Du; Peng Jiang
Journal:  Nat Metab       Date:  2022-02-28

Review 7.  Outcompeting cancer.

Authors:  Medhavi Vishwakarma; Eugenia Piddini
Journal:  Nat Rev Cancer       Date:  2020-01-13       Impact factor: 60.716

Review 8.  Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy.

Authors:  Isabella Giacomini; Federico Gianfanti; Maria Andrea Desbats; Genny Orso; Massimiliano Berretta; Tommaso Prayer-Galetti; Eugenio Ragazzi; Veronica Cocetta
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

9.  Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors.

Authors:  Patrícia M R Pereira; Komal Mandleywala; Ashwin Ragupathi; Jason S Lewis
Journal:  Clin Cancer Res       Date:  2020-09-30       Impact factor: 12.531

10.  Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.

Authors:  Özge Çiçek Şener; Adrian Stender; Tamara Isermann; Luisa Klemke; Nadine Winkler; Albrecht Neesse; Jinyu Li; Florian Wegwitz; Ute M Moll; Ramona Schulz-Heddergott
Journal:  Nat Commun       Date:  2021-06-29       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.